Skip to main content
Bioverativ reports on preliminary data for factor VIII candidate

Preliminary results from a Phase I/IIa study showed that one dose of Bioverativ's BIVV001, or rFVIIIFc-VWF-XTEN, resulted in a significant rise of factor VIII levels for seven days in people with severe hemophilia A, while also increasing factor VIII's half-life to 44 hours. The findings were presented at the American Society of Hematology's annual conference in December.

Full Story: